48,830
edits
Difference between revisions of "Squamous cell carcinoma of the lung"
Jump to navigation
Jump to search
Squamous cell carcinoma of the lung (view source)
Revision as of 16:29, 5 July 2016
, 16:29, 5 July 2016→IHC
(→IHC) |
|||
| Line 104: | Line 104: | ||
**Positive in [[adenocarcinoma of the lung]]. | **Positive in [[adenocarcinoma of the lung]]. | ||
SCC versus adenocarcinoma | ===SCC versus adenocarcinoma=== | ||
*p40 +ve. | *p40 +ve. | ||
*CK5/6 +ve. | *CK5/6 +ve. | ||
*TTF-1 -ve. | *TTF-1 -ve. | ||
*[[Napsin]] -ve. | *[[Napsin]] -ve. | ||
===Lung SCC versus metastatic bladder carcinoma=== | |||
As per Gruver ''et al.'':<ref name=pmid23106579>{{Cite journal | last1 = Gruver | first1 = AM. | last2 = Amin | first2 = MB. | last3 = Luthringer | first3 = DJ. | last4 = Westfall | first4 = D. | last5 = Arora | first5 = K. | last6 = Farver | first6 = CF. | last7 = Osunkoya | first7 = AO. | last8 = McKenney | first8 = JK. | last9 = Hansel | first9 = DE. | title = Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung. | journal = Arch Pathol Lab Med | volume = 136 | issue = 11 | pages = 1339-46 | month = Nov | year = 2012 | doi = 10.5858/arpa.2011-0575-OA | PMID = 23106579 }}</ref> | |||
{| class="wikitable sortable" | |||
! IHC | |||
! Lung SCC | |||
! Bladder [[urothelial carcinoma|UCC]] | |||
|- | |||
| CK7 | |||
| 33% +ve | |||
| 100% +ve | |||
|- | |||
| CK20 | |||
| 7% +ve | |||
| 54% +ve | |||
|- | |||
| GATA-3 | |||
| 23% +ve | |||
| 78% +ve | |||
|- | |||
| Desmoglein-3 | |||
| 87% +ve | |||
| 11% +ve | |||
|- | |||
| CK14 | |||
| 77% +ve | |||
| 32% +ve | |||
|- | |||
| Uroplakin III | |||
| 0% | |||
| 14% | |||
|} | |||
==Sign out== | ==Sign out== | ||